PHI News Room
All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews: Press Release
PHI granted patent on synthetic antibodies in the EU
PHI announces that the Company has been granted a patent on synthetic antibodies from the European Patent Office.
PostNews: Press Release
Directed issue registered at the Companies Registration Office
PHI Board of Directors’ proposal on a directed issue to Altium S.A. was resolved on the extraordinary general meeting on November 15, 2023. The directed issue has now been registered at the Swedish Companies Registration Office.
PostNews: Press Release
Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ) 15 november 2023
Phase Holographic Imaging PHI AB (publ) held an extraordinary general meeting on November 15, 2023. The following resolutions were passed at the meeting.
PostNews
BioStock: PHI’s CEO reflects on the Company’s momentum
BioStock reached out to PHI’s CEO, Patrik Eschricht, to delve into what latest developments have contributed to the heightened enthusiasm surrounding the company.
PostNews
BioStock: Altium fuels PHI’s forward drive
BioStock connects with Goran Dubravčić, Altium’s CEO and PHI’s newly appointed Chairman of the Board, to explore the current pivotal developments and their impact on PHI’s trajectory.
PostNews: Press Release
Bulletin from the annual general meeting of Phase Holographic Imaging PHI AB (publ)
Phase Holographic Imaging PHI AB (publ) held its annual general meeting on the 27th of October 2023. At the general meeting, the following resolutions were made.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
3D Culture
Using HoloMonitor and a public domain image processing software called Image J, the researchers from Northeastern University have developed a method for cell experiments based on cells cultured in a 3-dimensional collagen gel. They show that this new method is clearly superior to conventional methods, based on cells cultured on a 2-dimensional.
Big Pharma, Big Data
Imaged-based time-lapse cytometers, as our HoloMonitor, creates huge amounts of information on how cells interact and multiply over long time periods. Combined with Big Data technology, such novel instrumentation will provide cell biologists and the pharmaceutical industry with a game changing new tool to better understand complex cellular interactions and through this hopefully cure cancer.
Label-free High Content Screening
The current form of high-content screening is based on conventional microscopy. The core technology of HoloMonitor, holographic time-lapse microscopy, creates 3D-movies of unstained living cells that can be computer-processed without requiring the use of toxic labels. This new ability opens the door to more realistic high-content screening of living cells and their behavior over time.
Immunothearpy
The progress by Northeastern University and other customers have shown that HoloMonitor technology has the potential to be the non-destructive tool that makes large scale immunotherapies successful and affordable to all patients.
